HPS Pharmacies wish to advise that Mundipharma is discontinuing the following opioid products:
- OxyNorm® (oxycodone) capsules;
- MS Mono® (morphine sulfate) modified-release capsules; and
- Sevredol® (morphine sulfate) tablets
Mundipharma has provided the following estimated dates of discontinuation from the market based on current demand.
|Product||ARTG||Estimated discontinuation date|
|OxyNorm® 5mg||74145||March 2025|
|OxyNorm® 10mg||74143||June 2024|
|OxyNorm® 20mg||74141||March 2025|
|MS Mono® 30mg||74156||September 2024|
|MS Mono® 60mg||74154||October 2024|
|MS Mono® 90mg||74152||August 2024|
|MS Mono® 120mg||74150||September 2024|
|Sevredol® 10mg||47543||July 2024|
|Sevredol® 20mg||214089||April 2024|
These dates are estimates only and may be updated on the Medicine shortage reports database if there are any changes in demand.
Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Mundipharma on 1800 188 009 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates